Prescription Writing, Regulation, and Controlled Substances

AANP Family Nurse Practitioner Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical History & Lifespan Assessment

Section 1.1: Lifespan Health History: Newborn through Geriatric Care Section 1.2: Social Drivers of Health & Cultural Competence Section 1.3: Risk Assessment and Stratification

2 Chapter 2: Physical Examination & Physical Assessment

Section 2.1: Developmental Milestones & Pediatric Exams Section 2.2: Advanced Adult & Geriatric Physical Exams Section 2.3: Identifying Clinical Red Flags & Abuse/Neglect

3 Chapter 3: Diagnostic Screening, Testing, & Interpretation

Section 3.1: Primary Care Screening Guidelines Section 3.2: Interpreting Diagnostic Laboratory Panels Section 3.3: Ordering & Interpreting Imaging Studies Section 3.4: Electrocardiology & Pulmonary Function Tests

4 Chapter 4: Differential Diagnosis of Cardio-Respiratory & Endocrine Disorders

Section 4.1: Differentials in Cardiovascular Conditions Section 4.2: Differentials in Respiratory Conditions Section 4.3: Differentials in Endocrine and Metabolic Disorders

5 Chapter 5: Differential Diagnosis of GI, GU, & Reproductive Disorders

5.1 Differentials in Gastrointestinal Conditions 5.2 Differentials in Genitourinary and Renal Conditions 5.3 Differentials in Reproductive and Women's Health

6 Chapter 6: Differential Diagnosis of Neuro, MSK, Derm, & Psych Disorders

Section 6.1: Differentials in Musculoskeletal and Neurological Disorders Section 6.2: Differentials in Dermatological and Psychiatric Conditions

7 Chapter 7: Pharmacotherapeutic Principles & Prescribing Guidelines

Advanced Pharmacotherapeutic Principles Safe Prescribing in Special Populations Prescription Writing, Regulation, and Controlled Substances

8 Chapter 8: Evidence-Based Management of Common Primary Care Disorders

Section 8.1: Pharmacological Treatment Plans Section 8.2: Non-Pharmacological & Integrative Management Section 8.3: Referrals, Consultations, and Interprofessional Collaboration

9 Chapter 9: Health Promotion, Education, & Care Coordination

Section 9.1: Patient and Caregiver Education Section 9.2: Ethics, Consent, & Legal Scope in Treatment Planning

10 Chapter 10: Clinical Outcome Evaluation & Treatment Modification

Section 10.1: Monitoring Treatment Efficacy & Patient Adherence Section 10.2: Lab & Diagnostic Follow-Up in Care Monitoring Section 10.3: Identifying Adverse Drug Reactions & Complications Section 10.4: Criteria for Care Plan Modification & Escalation

Prescription Writing, Regulation, and Controlled Substances

Key Takeaways Explain This Topic AI

A valid prescription requires precise patient, provider, drug, dose, route, and refill specifications.

Error-reduction strategies include avoiding trailing zeros (write 5 mg), using leading zeros (write 0.5 mg), and avoiding banned abbreviations.

The DEA categorizes controlled substances into five schedules, with Schedule II drugs prohibiting any refills.

NPs must practice within state scope laws and check the Prescription Drug Monitoring Program (PDMP) to prevent diversion.

Prescribers must use Tall Man lettering to prevent errors between look-alike/sound-alike drugs (e.g., hydrOXYzine vs. hydrALAzine).

Last updated: November 2026

Prescription Writing, Regulation, and Controlled Substances

Prescribing medications legally and safely requires formatting accuracy, adherence to federal and state scope regulations, and the use of clinical monitoring databases.

Anatomy of a Safe Prescription

A complete and legally valid prescription must contain specific elements to ensure the pharmacist dispenses the correct medication, dose, and instructions.

Prescriber Information: Name, credentials (e.g., FNP-C, APRN), office address, phone, NPI, and DEA number (for controlled substances).

Patient Information: Full legal name, address, and date of birth.

Date of Issue: Required for determining the prescription's expiration date.

Inscription (Body): Drug name (generic preferred), strength (e.g., 250 mg), and dosage form (e.g., tablet, capsule, suspension).

Subscription: Instructions to the pharmacist, such as the quantity to dispense (e.g., Dispense: #30). For controlled substances, federal rules recommend writing the quantity in both numeric and written formats (e.g., 30 (thirty)) to prevent alteration.

Signatura (Sig): Instructions to the patient. This must include the route (e.g., PO, SL, topical), frequency (e.g., daily, every 8 hours), and specific indications for as-needed (PRN) medications (e.g., "for severe pain").

Refill Instructions: Must state the exact number of refills allowed or "no refills."

Signature: Signature of the prescriber.

Joint Commission "Do Not Use" List & Error Prevention

Prescribers must follow strict formatting rules to prevent dosing and transcription errors:

Never use trailing zeros: Write "5 mg", never "5.0 mg". If the decimal point is faintly printed, it can easily be misread as 50 mg.

Always use leading zeros: Write "0.5 mg", never ".5 mg". If the decimal point is missed, it can be misread as 5 mg.

Avoid dangerous abbreviations: The Joint Commission mandates that certain abbreviations be avoided. Do not use "U" or "u" for unit (can be misread as a zero or four). Do not use "IU" for International Unit (can be misread as IV). Do not use "QD" or "QOD" for daily or every other day (can be mistaken for each other). Do not use "MS" or "MSO4"; write out "morphine sulfate" (can be confused with magnesium sulfate, MgSO4).

Use appropriate units: For medications like levothyroxine, write the dose in micrograms (e.g., "50 mcg"), not milligrams ("0.05 mg"), to minimize decimal errors.

The Controlled Substances Act and DEA Schedules

The Controlled Substances Act (CSA) of 1970 categorizes regulated drugs into five schedules based on their medical utility and potential for abuse and dependence.

• DEA Schedule Abuse Potential Medical Use Refill Limits Examples
• Schedule I (C-I) High None None (Illegal) Heroin, LSD, MDMA
• Schedule II (C-II) High Accepted No Refills Allowed Morphine, Oxycodone, Fentanyl, Methylphenidate

Schedule III (C-III) Moderate-to-Low Accepted Max 5 refills / 6 months Buprenorphine, Ketamine, Anabolic Steroids, Tylenol #3

• Schedule IV (C-IV) Low Accepted Max 5 refills / 6 months Alprazolam, Clonazepam, Zolpidem, Tramadol
• Schedule V (C-V) Lowest Accepted Varies (State-limited) Promethazine with Codeine, Pregabalin, Lomotil

Schedule II (C-II) Regulations: Refills are strictly prohibited. A new prescription is required for each dispensing. Under federal law, emergency oral (verbal) prescriptions are permitted only under strict conditions (e.g., no alternative is available, immediate administration is necessary), must be limited to the amount needed to treat the emergency, and the prescriber must deliver a written or electronic "cover" prescription within seven days.

State Regulation and Provider Scope

While the DEA regulates controlled substances at the federal level, nurse practitioner prescribing authority is governed by state-level boards of nursing and legislatures. State laws dictate whether an NP has full practice authority (independent prescribing), reduced/collaborative practice (requires a collaborative practice agreement with a physician), or restricted/supervised practice (requires direct physician supervision and may bar Schedule II prescribing).

Prescription Drug Monitoring Program (PDMP)

The PDMP is a state-administered electronic database that tracks controlled substance prescriptions. In most states, NPs are legally mandated to check the PDMP before prescribing a controlled substance. The PDMP allows the clinician to detect "doctor shopping" (seeking controlled substances from multiple providers), identify duplicate prescriptions, and screen for drug diversion. It also alerts the NP to the dangerous co-prescribing of opioids and benzodiazepines, which synergistically increases the risk of fatal respiratory depression.

Avoiding Prescribing Errors: Look-Alike/Sound-Alike Drugs

Prescribers must remain vigilant against Look-Alike/Sound-Alike (LASA) drug errors. The FDA and Institute for Safe Medication Practices (ISMP) recommend using "Tall Man Lettering" to highlight differences.

hydrOXYzine (an antihistamine used for anxiety or pruritus) vs. hydrALAzine (a direct vasodilator used for hypertension). Mixing these up can lead to severe hypotension or profound sedation.

ZYPREXA (olanzapine) vs. ZYRTEC (cetirizine).

Worked Scenario: PDMP and Early Refill Request

A 45-year-old male with chronic lumbar radiculopathy presents to the clinic requesting an early refill of Schedule II oxycodone/acetaminophen, stating his prescription was accidentally destroyed when his water bottle leaked. The NP's first step is to query the state's PDMP database. The report reveals the patient has filled early opioid prescriptions from two other providers at different pharmacies in the last two months. Recognizing this pattern of "doctor shopping," the NP denies the early refill request. The NP discusses the PDMP findings with the patient, reviews the signed controlled substance agreement, offers non-narcotic alternative therapies (such as physical therapy referral or a gabapentinoid trial), and screens him for opioid use disorder. The entire encounter and clinical rationale are meticulously documented in the electronic health record.